AVBP ARRIVENT BIOPHARMA INC revenue, earnings and financials
For the quarter ended June 30, 2026, ARRIVENT BIOPHARMA INC reported revenue of n/a, net income of −$49.9M and diluted EPS of −$1.05; for the fiscal year ended December 2025 revenue was n/a.
AVBP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$178M, net income −$166M (margin n/a), EPS −$4.32
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$94.3M, net income −$80.5M (margin n/a), EPS −$2.56
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$74.6M, net income −$69.3M (margin n/a), EPS −$32.38
AVBP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$49.9M, EPS −$1.05
- Quarter ended Mar 31, 2026: revenue n/a, net income −$43.3M, EPS −$0.96
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$35.5M, EPS −$0.69
- Quarter ended Sep 30, 2025: revenue n/a, net income −$35.0M, EPS −$0.83
- Quarter ended Jun 30, 2025: revenue n/a, net income −$31.4M, EPS −$0.90
- Quarter ended Mar 31, 2025: revenue n/a, net income −$64.4M, EPS −$1.90
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$20.6M, EPS −$0.60
- Quarter ended Sep 30, 2024: revenue n/a, net income −$20.6M, EPS −$0.61
- Quarter ended Jun 30, 2024: revenue n/a, net income −$21.9M, EPS −$0.65
- Quarter ended Mar 31, 2024: revenue n/a, net income −$17.4M, EPS −$0.70
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$21.2M, EPS −$6.62
- Quarter ended Sep 30, 2023: revenue n/a, net income −$14.4M, EPS −$5.52
- Quarter ended Jun 30, 2023: revenue n/a, net income −$21.6M, EPS −$10.79
- Quarter ended Mar 31, 2023: revenue n/a, net income −$12.2M, EPS −$9.45
AVBP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$161M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$70.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$55.8M, share buybacks n/a
AVBP balance sheet
- Jun 30, 2026: cash $155M, total assets $395M, total liabilities $27.9M, shareholders' equity $367M
- Mar 31, 2026: cash $62.1M, total assets $349M, total liabilities $25.3M, shareholders' equity $324M
- Dec 31, 2025: cash $45.5M, total assets $333M, total liabilities $25.9M, shareholders' equity $307M
- Sep 30, 2025: cash $113M, total assets $327M, total liabilities $21.6M, shareholders' equity $305M
- Jun 30, 2025: cash $113M, total assets $270M, total liabilities $19.6M, shareholders' equity $250M
- Mar 31, 2025: cash $49.9M, total assets $215M, total liabilities $13.0M, shareholders' equity $203M
- Dec 31, 2024: cash $74.3M, total assets $275M, total liabilities $17.3M, shareholders' equity $258M
- Sep 30, 2024: cash $283M, total assets $293M, total liabilities $15.2M, shareholders' equity $277M
Is AVBP profitable?
No. ARRIVENT BIOPHARMA INC lost $164M over the last four quarters.
What is AVBP's EPS?
Diluted earnings per share over the last four quarters were −$3.53; −$1.05 in the latest quarter.